| Bloom syndrome DNA helicase deficiency is associated with oxidative stress and mitochondrial network changes V Subramanian, B Rodemoyer, V Shastri, LJ Rasmussen, C Desler, ... Scientific Reports 11 (1), 2157, 2021 | 20 | 2021 |
| Cellular defects caused by hypomorphic variants of the Bloom syndrome helicase gene BLM VM Shastri, KH Schmidt Molecular genetics & genomic medicine 4 (1), 106-119, 2016 | 19 | 2016 |
| A novel cell-cycle-regulated interaction of the Bloom syndrome helicase BLM with Mcm6 controls replication-linked processes VM Shastri, V Subramanian, KH Schmidt Nucleic Acids Research 49 (15), 8699-8713, 2021 | 9 | 2021 |
| A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials MO Gbadamosi, VM Shastri, AH Elsayed, R Ries, O Olabige, ... Leukemia 36 (8), 2022-2031, 2022 | 8 | 2022 |
| Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms MO Gbadamosi, VM Shastri, T Hylkema, I Papageorgiou, L Pardo, ... Future Oncology 17 (03), 263-277, 2021 | 7 | 2021 |
| Polygenic pharmacogenomic markers as predictors of toxicity phenotypes in the treatment of acute lymphoblastic leukemia: a single-center study T Larkin, R Kashif, AH Elsayed, B Greer, K Mangrola, R Rafiee, N Nguyen, ... JCO Precision Oncology 7, e2200580, 2023 | 3 | 2023 |
| Pharmacogenomic single nucleotide polymorphism (SNP) variants as predictors of toxicity phenotypes in the treatment of acute childhood leukemia R Kashif, T Larkin, AH Elsayed, NHK Nguyen, N Emanuel, VM Shastri, ... Blood 138, 3360, 2021 | 1 | 2021 |
| The rs35112940 CD33 polymorphism reduces CD33 internalization and efficacy of CD33-directed Gemtuzumab Ozogamicin MO Gbadamosi, VM Shastri, S Meshinchi, JK Lamba Blood 138, 2247, 2021 | 1 | 2021 |
| Abstract P18: Splicing polymorphism rs12459419 modulates antibody-bound internalization of CD33 isoforms VM Shastri, JK Lamba Blood Cancer Discovery 5 (2_Supplement), P18-P18, 2024 | | 2024 |
| DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's … VM Shastri, L Chauhan, M Gbadamosi, TA Alonzo, YC Wang, R Aplenc, ... Clinical Cancer Research, OF1-OF9, 2024 | | 2024 |
| Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group. VM Shastri, L Chauhan, M Gbadamosi, TA Alonzo, YC Wang, R Aplenc, ... Clinical Cancer Research: an Official Journal of the American Association …, 2024 | | 2024 |
| ACS10-Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients RJ Marrero, VM Shastri, R Aplenc, T Cooper, TA Alonzo, AS Gamis, ... Blood 142, 4314, 2023 | | 2023 |
| Splicing Polymorphism rs12459419 Modulates Antibody-Bound Internalization of CD33 Isoforms VM Shastri, MO Gbadamosi, JK Lamba Blood 142, 5749, 2023 | | 2023 |
| Pharmacogenomics to Predict Asparaginase Premedication-Related Hypersensitivity in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma VM Shastri, J Ahmed, E Spin, Y Nunez, S Morales, A Agrawal, CL Phillips, ... Blood 142, 6067, 2023 | | 2023 |
| Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients RJ Marrero, D Nicolet, VM Shastri, K Mrózek, CJ Walker, W Blum, ... Blood 142, 2954, 2023 | | 2023 |
| Cd33 antibodies JK Lamba, MO Gbadamosi, V Shastri US Patent App. 18/026,195, 2023 | | 2023 |
| Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia SR Nittu, F Marchi, N Nguyen, VM Shastri, X Cao, RC Ribeiro, JE Rubnitz, ... Blood 142 (Supplement 1), 2926-2926, 2023 | | 2023 |
| PHARMACOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORES AS A TOOL TO PREDICT TOXICITY PHENOTYPES IN TREATMENT OF ACUTE CHILDHOOD LEUKEMIA (ALL). N Nguyen, R Kashif, T Larkin, A Elsayed, N Emanuel, V Shastri, R Rafiee, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S65-S65, 2022 | | 2022 |
| A POLYGENIC DNA DAMAGE REPAIR PHARMACOGENOMICS (DDR_PGX) SCORE PREDICTS RESPONSE TO GEMTUZUMAB OZOGAMICIN IN PEDIATRIC AML PATIENTS. V Shastri, L Chauhan, T Alonzo, Y Wang, R Aplenc, B Hirsch, A Gamis, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S67-S67, 2022 | | 2022 |
| Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant VM Shastri, TA Hylkema, MO Gbadamosi, S Meshinchi, JK Lamba Blood 138, 1290, 2021 | | 2021 |
